CytoBioscience, Inc.
No Reviews Yet
No Completed Orders
San Antonio, Texas, US
Our Specialty is in vitro safety pharmacology
…We don’t just provide data, we provide solutions
With decades of ion channel experience, CytoBioScience is uniquely positioned to be your one stop shop for in vitro safety pharmacology. From the CiPA ion channel panel to stem cells and in silico modeling, all aspects of the safety characterization of your compounds can be carried out. We also offer GLP capabilities and dose formulation analysis.
The new strategy, entitled “Comprehensive
In Vitro Proarrhythmia Assay” (CiPA), shifts the emphasis
away from QT-prolongation and focuses on predicting
proarrhythmic torsadogenic hazard risk through an
expansion of the in vitro component of nonclinical safety
evaluation, which could be performed in the discovery
stage of drug development to guide selection of candidate
compounds with the most favorable profiles. This new approach is intended to provide a
more accurate representation of the torsadogenic potential
compared to the current focus on delayed repolarization.
It is anticipated that CiPA will reduce or eliminate the
necessity for conducting a thorough QT study during clinical
development.
The human ether-a-go-go related gene (hERG) encodes the inward rectifying voltage gated potassium channel in the heart (IKr) which is involved in cardiac repolarisation.
Inhibition of the hERG current causes QT interval prolongation resulting in potentially fatal ventricular tachyarrhythmia called Torsade de Pointes. If hERG inhibition occurs we recommend CiPA assays as second phase.
Microelectrode array assay is used to determine cardiac action potential and/or ion channel activity using Human iPSC-Cardio Myocytes
Drug Discovery & Development Services
Electrophysiology Services
CytoBioscience, Inc. has not received any reviews.
CytoBioscience, Inc. has not received any endorsements.